RT Journal Article
SR Electronic
T1 Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.05.23286816
DO 10.1101/2023.03.05.23286816
A1 Lingas, Guillaume
A1 Planas, Delphine
A1 Péré, Hélène
A1 Duffy, Darragh
A1 Staropoli, Isabelle
A1 Porrot, Françoise
A1 Guivel-Benhassine, Florence
A1 Chapuis, Nicolas
A1 Gobeaux, Camille
A1 Veyer, David
A1 Delaugerre, Constance
A1 Goff, Jérôme Le
A1 Getten, Prunelle
A1 Hadjadj, Jérôme
A1 Bellino, Adèle
A1 Parfait, Béatrice
A1 Treluyer, Jean-Marc
A1 Schwartz, Olivier
A1 Guedj, Jérémie
A1 Kernéis, Solen
A1 Terrier, Benjamin
YR 2023
UL http://medrxiv.org/content/early/2023/03/06/2023.03.05.23286816.abstract
AB Background While anti-SARS-CoV-2 antibody kinetics have been well described in large populations of vaccinated individuals, we still poorly understand how they evolve during a natural infection and how this impacts viral clearance.Methods For that purpose, we analyzed the kinetics of both viral load and neutralizing antibody levels in a prospective cohort of individuals during acute infection by Alpha variant.Results Using a mathematical model, we show that the progressive increase in neutralizing antibodies leads to a shortening of the half-life of both infected cells and infectious viral particles. We estimated that the neutralizing activity reached 90% of its maximal level within 8 days after symptoms onset and could reduce the half-life of both infected cells and infectious virus by a 6-fold factor, thus playing a key role to achieve rapid viral clearance. Using this model, we conducted a simulation study to predict in a more general context the protection conferred by the existence of pre-existing neutralization, due to either vaccination or prior infection. We predicted that a neutralizing activity, as measured by ED50 >103, could reduce by 50% the risk of having viral load detectable by standard PCR assays and by 99% the risk of having viral load above the threshold of cultivable virus.Conclusions This threshold value for the neutralizing activity could be used to identify individuals with poor protection against disease acquisition.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04703114Funding StatementThe AMBUCOV study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology. An additional grant was obtained for immunological and virological experiments (COVID-19 grant number COV21039). The funding sources had no role in the study's design, conduct, and reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB C.P.P. Ile de France III approved the study protocol prior to data collection (approval number Am8849-2-3853-RM) and all subsequent amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll codes, datasets for the modelling analysis and datasets for the figures, supplementary figures, tables and supplementary tables are available at .